IMVT-1402

N/A

Report date: 2026/05/23 20:00:57

Base Information

Drug NameIMVT-1402
Drug Alias NameIMVT-1402HL-161 ANS
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionIgG receptor FcRn large subunit p51 antagonists
TargetsIgG receptor FcRn large subunit p51
Therapy Area/IndicationsAutoimmune DiseasesLupus Erythematosus, CutaneousGraves Disease +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBosnia and Herzegovina +[39] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesHanAll Biopharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesRoivant Sciences LtdImmunovant IncImmunovant Sciences Gmbh
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesLupus Erythematosus, CutaneousGraves Disease +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A